Company Profile
PMV Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- PMVP
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.18 USD (+0.85%)
Close
Last updated: August 6, 2026
62.9M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, PMVP closed up 0.85% at $1.18. No new same-company headline was identified in the current news window.
Company overview
Mutant p53 Precision Oncology
PMV Pharmaceuticals develops small molecules that restore activity to specific mutant forms of the tumor suppressor p53.
Rezatapopt
Rezatapopt selectively binds the TP53 Y220C mutant and is designed to restore wild-type p53 structure and tumor-suppressor function.
Ovarian Cancer Lead Indication
The PYNNACLE program is focused on platinum-resistant or refractory ovarian cancer carrying TP53 Y220C, with broader solid-tumor development also underway.
Future catalysts
PMV plans to submit an NDA for rezatapopt in TP53 Y220C-positive platinum-resistant or refractory ovarian cancer in the first quarter of 2027.
Recent news
- 01
PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights
Source: PMV Pharmaceuticals
- 02
PMV Pharmaceuticals Announces Board Chair Transition
Source: PMV Pharmaceuticals
- 03
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
Source: PMV Pharmaceuticals
- 04
- 05
PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights
Source: PMV Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of PMV Pharmaceuticals (PMVP)?
PMV Pharmaceuticals (PMVP) most recently closed at 1.18 USD, a +0.85% move versus the previous session.
What is the market cap of PMV Pharmaceuticals (PMVP)?
PMV Pharmaceuticals currently has a market capitalization of 62.9M USD on BioPharmSignal.
What does PMV Pharmaceuticals do?
Mutant p53 Precision Oncology PMV Pharmaceuticals develops small molecules that restore activity to specific mutant forms of the tumor suppressor p53. Rezatapopt Rezatapopt selectively binds the TP53 Y220C mutant and is designed to restore wild-type p53 structure and tumor-suppressor function. Ovarian Cancer Lead Indication The PYNNACLE program is focused...
On which exchange is PMVP stock listed?
PMV Pharmaceuticals (PMVP) is associated with NASDAQ, United States, Biopharma.
What is Mutant?
Mutant p53 Precision Oncology PMV Pharmaceuticals develops small molecules that restore activity to specific mutant forms of the tumor suppressor p53.
Which conditions is PMV Pharmaceuticals targeting with Mutant?
PMV Pharmaceuticals is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does PMV Pharmaceuticals describe recent progress with Mutant?
PMV plans to submit an NDA for rezatapopt in TP53 Y220C-positive platinum-resistant or refractory ovarian cancer in the first quarter of 2027.
What is Precision?
Mutant p53 Precision Oncology PMV Pharmaceuticals develops small molecules that restore activity to specific mutant forms of the tumor suppressor p53.